Therefore, the management of hypertension in the context of AF requires highly tailored therapy specific to the patient phenotype—such as RAAS inhibitors for fibrosis-prone individuals, β-blockers for those with heightened sympathetic activity, and mineralocorticoid receptor antagonists for resistant hypertension—in order to optimise hypertension-driven AF prevention and address the dominant mechanisms driving arrhythmogenesis within each phenotype. Here, NR3C2 is linked to hypertensive disorder.